VFA
GCVRZ

Valeo Financial Advisors’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

Valeo Financial Advisors’s Portfolio GCVRZ Stock Details GCVRZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-6
Closed – – 1943
2018
Q2 		$0 Hold
6
– – ﹤0.01% 1849
2018
Q1 		$0 Buy
+6
New +$2 ﹤0.01% 1662

Other funds holding GCVRZ

SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
MCM
Mason Capital Management New York $613M AUM 21.43% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
NGA
New Generation Advisors Manchester, Massachusetts $45.6M AUM 15.43% 1-Year Est. Return

Valeo Financial Advisors's GCVRZ Position: Q3 2018 in Review

Valeo Financial Advisors sold out of Sanofi Contingent Value Rights (GCVRZ) in Q3 2018, closing a stake of 6 shares.

Valeo Financial Advisors first reported a position in GCVRZ in Q1 2018 and held it in 2 quarters. The position peaked at $0 in Q2 2018. 106 funds tracked by Wall St. Rank hold GCVRZ as of Q3 2018.

  • Valeo Financial Advisors reported no remaining Sanofi Contingent Value Rights position as of Q3 2018 after selling out during the quarter.
  • Valeo Financial Advisors sold 6 Sanofi Contingent Value Rights shares in Q3 2018.
  • Valeo Financial Advisors first reported a position in Sanofi Contingent Value Rights in Q1 2018 and held it in 2 quarters.
  • Valeo Financial Advisors's Sanofi Contingent Value Rights position peaked at $0 in Q2 2018.
  • 106 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q3 2018.

Based on Valeo Financial Advisors's 13F filing for Q3 2018, filed 1 Nov 2018.